HOME >> BIOLOGY >> NEWS
24-Wk data from CONTEXT trial comparing GW433908/ritonavir QD & BID to Lopinavir/ritonavir BID

International Congress on Drug Therapy in HIV Infection in Glasgow, United Kingdom.

Efficacy Results From CONTEXT

A total of 320 (315 treated) PI-experienced HIV+ patients experiencing virologic failure (plasma HIV-1 RNA viral load of ?1,000 copies/mL) were enrolled in the CONTEXT study. Forty percent of study participants had prior treatment experience with two or more PIs, 74 percent had experience with 3 or more nucleoside reverse transcriptase inhibitors (NRTIs), and 57 percent had received prior therapy with non-nucleoside reverse transcriptase inhibitors (NNRTIs).

Patients were randomized to receive either 1400 mg of 908 QD combined with low dose ritonavir (200 mg QD) (n=105), 700 mg of 908 combined with 100 mg ritonavir BID (n=107), or 400 mg lopinavir/100 mg ritonavir BID (n=103). All three groups took the medications in combination with two active NRTIs. Baseline vRNA (median 4.14 log10 copies/mL) and CD4+ cell counts (median 263 cells/mm3 ) were similar among the treatment arms.

By intent-to-treat analysis at 24 weeks, the mean AAUCMB (log10 c/mL) was -1.48 for patients on 908/r QD, -1.50 for those on 908/r BID and -1.66 for those taking LPV/r BID, according to DeJesus. Positive antiviral responses were seen with both the 908/r and LPV/r regimens, with 48 percent, 42 percent and 40 percent achieving <50 c/mL responses in the LPV/r, 908/r QD and 908/r BID arms, respectively. The median change from baseline in CD4 cells/mm3 was 72 for 908/r QD, 62 for 908/r BID and 63 for LPV/r BID.

Safety Results from CONTEXT

In the CONTEXT trial, the incidence of drug-related adverse events (AEs) of at least moderate severity was low, occurring in 19 percent of patients on 908/r QD (n=20), 35 percent on 908/r BID (n=37) and 34 percent on LPV/r BID (n=35). The most common AEs were diarrhea (5 percent, 10 percent and 8 percent, respectively) and nausea (4 percent, 3 percent and 9 percent, respectively). Additionally, mo
'"/>

Contact: Amy Kling
akling@pcipr.com
312-558-1770
Public Communications Inc.
14-Feb-2003


Page: 1 2 3 4

Related biology news :

1. Phase II trials of second-generation antisense cancer drug planned following successful early study
2. Innovative ceramic-on-metal hip replacements to undergo clinical trials
3. Creation of the UK Clinical Research Collaboration will boost clinical trials in UK
4. Novel therapeutic bortezomib moves to phase II trial in lung cancer patients
5. Pharmacogenomics could replace trial-and-error with science from the human genome
6. Wilex & Fox Chase Cancer Center begin trial w/ novel compound targeting tumor invasion & metastasis
7. Small trial shows daclizumab add-on therapy improves MS outcome
8. Tigecycline - antibiotic evaluated in surveillance trial
9. OneWorld Health completes enrollment, treatment in Phase III India trial
10. Landmark, pivotal Phase IIb/III trial of biotoxin for cancer pain begins
11. First large-scale trial of genetically personalised treatment for breast cancer to start soon

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:3/28/2017)... , March 28, 2017 The ... Hardware (Camera, Monitors, Servers, Storage Devices), Software (Video Analytics, ... Region - Global Forecast to 2022", published by MarketsandMarkets, ... 2016 and is projected to reach USD 75.64 Billion ... and 2022. The base year considered for the study ...
(Date:3/24/2017)... 24, 2017 The Controller General of Immigration from ... Abdulla Algeen have received the prestigious international IAIR Award for the ... Continue Reading ... ... Controller Abdulla Algeen (small picture on the right) have received the IAIR ...
(Date:3/23/2017)... The report "Gesture Recognition and Touchless Sensing Market by Technology (Touch-based ... to 2022", published by MarketsandMarkets, the market is expected to be worth USD ... 2022. Continue Reading ... ... ...
Breaking Biology News(10 mins):
(Date:10/11/2017)... and LAGUNA HILLS, Calif. , Oct. ... Cancer Research, London (ICR) and University ... SKY92, SkylineDx,s prognostic tool to risk-stratify patients with multiple myeloma ... MUK nine . The University of Leeds ... partly funded by Myeloma UK, and ICR will perform the ...
(Date:10/10/2017)... ... 2017 , ... San Diego-based team building and cooking events company, Lajollacooks4u, has ... The bold new look is part of a transformation to increase awareness, appeal to ... period. , It will also expand its service offering from its signature gourmet cooking ...
(Date:10/10/2017)... 10, 2017 International research firm Parks Associates announced ... at the TMA 2017 Annual Meeting , October 11 in ... residential home security market and how smart safety and security products impact ... Parks Associates: Smart Home ... "The residential security market has ...
(Date:10/9/2017)... DIEGO , Oct. 9, 2017  BioTech ... biological mechanism by which its ProCell stem cell ... critical limb ischemia.  The Company, demonstrated that treatment ... amount of limbs saved as compared to standard ... the molecule HGF resulted in reduction of therapeutic ...
Breaking Biology Technology:
Cached News: